Amylyx Pharmaceuticals Inc (AMLX)
1.83
+0.03
(+1.67%)
USD |
NASDAQ |
May 22, 16:00
1.83
0.00 (0.00%)
After-Hours: 05:54
Amylyx Pharmaceuticals Accounts Receivable (Quarterly): 20.35M for March 31, 2024
Accounts Receivable (Quarterly) Chart
Historical Accounts Receivable (Quarterly) Data
| Date | Value |
|---|---|
| March 31, 2024 | 20.35M |
| December 31, 2023 | 40.05M |
| September 30, 2023 | 29.35M |
| June 30, 2023 | 33.47M |
| March 31, 2023 | 17.56M |
| Date | Value |
|---|---|
| December 31, 2022 | 15.31M |
| September 30, 2022 | 0.137M |
| June 30, 2022 | |
| March 31, 2022 | |
| December 31, 2021 | 0.00 |
Accounts Receivable Definition
Account used to record sales made "on account", meaning that the company has made a sale but has not collected payment. When company collects cash as payment, the corresponding account receivable is decreased.
Accounts Receivable (Quarterly) Range, Past 5 Years
--
Minimum
Dec 2021
40.05M
Maximum
Dec 2023
19.53M
Average
18.95M
Median
Accounts Receivable (Quarterly) Benchmarks
| Cassava Sciences Inc | -- |
| iRhythm Technologies Inc | 89.71M |
| Bristol-Myers Squibb Co | 8.826B |
| Moderna Inc | 137.00M |
| ACADIA Pharmaceuticals Inc | 94.70M |